There are 2789 resources available
700P - Efficacy of sacituzumab govitecan (SG) by trophoblast cell surface antigen 2 (Trop-2) expression in patients (Pts) with metastatic urothelial cancer (mUC)
Presenter: Yohann Loriot
Session: ePoster Display
638P - Evaluating the contribution of virtual peer-led support to comprehensive prostate cancer (PCa) care: The AnCan experience
Presenter: Herbert Geller
Session: ePoster Display
640TiP - Phase Ib/II trial of pembrolizumab (pembro) + lenvatinib combination therapy in patients (pts) with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE): KEYNOTE-365 cohorts E and F
Presenter: Gero Kramer
Session: ePoster Display
641TiP - Phase Ib/II trial of pembrolizumab (pembro) + vibostolimab combination therapy in patients (Pts) with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE): KEYNOTE-365 cohorts G and H
Presenter: Johann de Bono
Session: ePoster Display
642TiP - Phase II CA184-585 (INSPIRE) trial of ipilimumab with nivolumab for molecular-selected patients with castration-resistant prostate cancer
Presenter: Niven Mehra
Session: ePoster Display
643TiP - Open-label, phase II study of ladiratuzumab vedotin (LV) for unresectable locally advanced or metastatic solid tumors
Presenter: Hendrik-Tobias Arkenau
Session: ePoster Display
711P - Outcomes according to genomic characteristics of patients with metastatic urothelial carcinoma in phase I/II trials
Presenter: Cedric Pobel
Session: ePoster Display
712P - Analysis of fibroblast growth factor receptor 3 aberrations in bladder cancer, for enabling personalized and effective therapy based on FGFR inhibitor
Presenter: Roman Sosnowski
Session: ePoster Display
713P - Assessment of bleomycin pulmonary toxicity in men with poor-prognosis non-seminomatous germ-cell tumors treated in the GETUG 13 phase III trial
Presenter: Natacha Naoun
Session: ePoster Display